<DOC>
	<DOCNO>NCT00096603</DOCNO>
	<brief_summary>This open label , multicenter study design evaluate safety tolerability efalizumab administer subcutaneously weekly dos 1.0 mg/kg subject plaque psoriasis previously participate Study ACD2600g .</brief_summary>
	<brief_title>A Study Evaluate Safety Raptiva Adults With Plaque Psoriasis Previously Enrolled Study ACD2600g</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Signed informed consent Previous participation Study ACD2600g For woman childbearing potential , continue use acceptable method contraception duration study Any medical condition , judgment investigator , would jeopardize subject 's safety follow exposure Efalizumab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Moderate severe plaque psoriasis</keyword>
</DOC>